GlobeNewswire by notified

PCI Biotech: Company update

Share

Oslo (Norway), 18 August 2022 – PCI Biotech (OSE: PCIB), a cancer-focused biopharma company developing innovative therapeutics that address significant unmet medical needs, today announced that the previously reported efforts to finance a planned Ph II trial in head and neck cancer have not under the current market conditions resulted in a feasible way forward.

As PCI Biotech will not conduct a company-sponsored Ph II trial with the fimaVacc technology a reduction of the clinical team will be enacted during the second half of 2022. Further details about the development plans for the non-clinical assets will be given at the upcoming Q2 reporting, scheduled 31st August 2022. The cash position per Q2 2022 is around NOK 76 million and the financial runway is estimated to be towards the end of 2023.

Contact information:        
Ronny Skuggedal, Interim CEO        
rs@pcibiotech.no
Mobile: +47 9400 5757

About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities. The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.

For further information, please visit: www.pcibiotech.com

Forward-looking statements        
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.


To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Global Health and Gavi Veteran Anuradha Gupta to Lead Global Immunization at Sabin3.10.2022 16:00:00 CEST | Press release

WASHINGTON, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Veteran public health leader Anuradha Gupta, who has spearheaded a host of successful global initiatives to improve the health of women and children and boost vaccine access and uptake, has joined Sabin Vaccine Institute as President of Global Immunization. Gupta’s record of crafting and implementing creative solutions to seemingly intractable health challenges is particularly significant now with life-saving childhood immunizations sustaining their largest backslide in decades, fueled largely by the pandemic. Gupta comes to Sabin after eight years with Gavi, the Vaccine Alliance, where she served as Deputy CEO and led efforts to center policies, programs and partnerships around vaccine equity, gender and communities. She also pioneered the concept of zero-dose children – those who have not received a single dose of the most basic vaccines – and drove efforts to create a new model of country-level partnerships. “Anuradha Gupta is a stellar

Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial3.10.2022 14:02:33 CEST | Press release

Bagsværd, Denmark, 3October 2022 – Novo Nordisk today announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting including fewer trial visits compared to the other ONWARDS phase 3a trials. Once-weekly insulin icodec was used in combination with a dosing guide app to guide titration. The trial achieved its primary endpoint of demonstrating non-inferiority in reducing HbA1c at week 52 with insulin icodec compared with once-daily basal insulin analogues. From an overall baseline HbA1c of 8.9%, once-weekly insulin icodec achieved a superior reduction in estimated HbA1c of –1.68%-points compared with –1.31%-points for the once-daily basal insulin

Cellebrite Appoints Adv. Ayala Berler Shapira as General Counsel3.10.2022 13:00:00 CEST | Press release

PETAH TIKVA, Israel and TYSONS CORNER, Va., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Cellebrite DI Ltd. (Nasdaq: CLBT), a global leader in Digital Intelligence (DI) solutions for the public and private sectors, today announced that Ayala Berler Shapira has been named General Counsel (GC) of the company. As part of the company’s further growth Ayala Berler Shapira will strategically manage all legal aspects and will assume complete responsibility and lead the legal and compliance organization of Cellebrite. She will be a member of Cellebrite’s executive management team. Ayala brings 27 years of experience in both global technology companies and in some of the leading law firms in Israel. Prior to joining Cellebrite, Ayala served as Deputy GC of Amdocs, where she led the global business and corporate legal domains, supported the company’s M&A activity, and served as Head of Compliance. Before that, she was the GC of Jungo, an Israeli software company operating in the telecommunication market. A

Correction: Notice on Convocation of Extraordinary General Meeting of Shareholders of AB Klaipėdos nafta3.10.2022 12:56:56 CEST | Press release

Correction of Annex No 1 (Draft decision) and Annex No 2 (Ballot paper) was made. Notice is hereby given that on the initiative and by the resolution of the Board of AB Klaipėdos nafta, legal entity code 110648893, with the registered office at Burių str. 19, Klaipeda (hereinafter - the Company), Exraordinary General Meeting of Shareholders of the Company will be held on 20 October 2022 at 1:00 p.m. The meeting will be held in the Company’s office at Buriu str. 19, Klaipeda, in the administrative office of the Company (in the hall of the meeting on the 2nd floor). Agenda of the meeting: Regarding the approval of amendment of Remuneration Policy of AB Klaipėdos nafta. The shareholders will be registered from 12:00 a.m. to 12:55 p.m. The persons intending to participate in the meeting shall have a personal ID document (an authorized representative shall have an authorization approved under the established procedure. The natural person’s authorization shall be notarized. An authorization

eGain named a Representative Vendor in the 2022 Gartner® Market Guide for Customer Service Knowledge Management Systems3.10.2022 12:30:00 CEST | Press release

SUNNYVALE, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- eGain Corporation (NASDAQ: EGAN), the leading knowledge management platform provider for customer engagement automation, today announced that it has been named in the 2022 Gartner Market Guide for Customer Service Knowledge Management Systems. “In 2022, 74% of Customer Service and Support (CSS) leaders cited improving knowledge and content delivery to customers and employees as a priority. In the absence of direct peer interactions when working from home, reps will need in-the-moment, personalized, contextually aware information within the flow of work in order to assist customers and resolve their requests,” wrote authors Pri Rathnayake and Drew Kraus in the Guide. The report provides an overview of the market, outlines trends and challenges, and offers a framework to evaluate vendor capabilities to help enterprise leaders select the right platform and partner for their knowledge initiatives. Vendors were evaluated across three cate